Related references
Note: Only part of the references are listed.Denosumab and bisphosphonates: Different mechanisms of action and effects
Roland Baron et al.
BONE (2011)
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
H. K. Genant et al.
BONE (2010)
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
David L. Kendler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Microarchitectural Deterioration of Cortical and Trabecular Bone: Differing Effects of Denosumab and Alendronate
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Monitoring osteoporosis treatment
Juliet Compston
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate
O. Bruyere et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Olivier Bruyere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD
NB Watts et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
PJ Kostenuik
CURRENT OPINION IN PHARMACOLOGY (2005)
Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses
PD Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
NB Watts et al.
JOURNAL OF CLINICAL DENSITOMETRY (2004)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
MC Hochberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
SR Cummings et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy
S Sarkar et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A method to assess the proportion of treatment effect explained by a surrogate endpoint
ZQ Li et al.
STATISTICS IN MEDICINE (2001)
Antifracture efficacy of antiresorptive agents are related to changes in bone density
RD Wasnich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)